ACP3 and prostate carcinoma: DCs are harvested from patients via leukapheresis and incubated with a fusion protein of prostatic acid phosphatase (PAP) prostate antigen and GMCSF, which matures the DCs and helps direct immune responses against prostate cancer cells expressing high amounts of PAP in vivo.